View
9
Download
0
Category
Preview:
Citation preview
10/8/21
1
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Deprescribing:A Proactive Approach to
Prevent Geriatric Syndromes
Katie Connolly, PharmD, MS, BCGP, CPE
Ryan J. Connolly, DO, MS, FACOI
1
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Meet the Speakers: Katie Connolly, PharmD, MS, BCGP
• Clinical Pharmacist, Medical University of South Carolina
• Masters of Science in Medical Education
• Board Certified Geriatric Pharmacist
• Certified Pain Educator
2
10/8/21
2
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Meet the Speakers: Ryan J. Connolly, DO, MS, FACOI
• Internal Medicine Physician, Roper St. Francis Health System
• Medical Director, Hospital at Home Program
• Masters of Science in Medical Education
• Fellow of the American College of Osteopathic Internists
3
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Disclosure
• The speakers have no actual or potentially relevant financial relationship to disclose and no conflict of interest in relation to this activity.
4
10/8/21
3
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Pharmacist Learning Objectives
• Describe the relationship between polypharmacy and geriatric syndromes • Identify methods by which pharmacists and physicians can work
together to optimize the medication regimens of older adults• Describe tools that can be used to safely deprescribe medications • Utilize deprescribing to reduce the risk of potential adverse events in
geriatric patients
5
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Pharmacy Technician Learning Objectives
• Define polypharmacy, geriatric syndromes, and deprescribing• Describe how deprescribing can be utilized to prevent adverse events • Identify medications that may increase the risk of geriatric
syndromes in an older adult
6
10/8/21
4
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Background
7
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Geriatric Patients
Polypharmacy
Geriatric Syndromes
Multi-morbidity
Age Related Changes
Functional & Cognitive Limitations
Limited Evidence
8
10/8/21
5
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Polypharmacy
• “The simultaneous use of multiple drugs by a single patient, for one or more conditions”• Can be defined by quantity
• Commonly, five or more medications• Range from two or more to greater than 10 meds
• Associated with multimorbidity and geriatric syndromes• Increases risk of adverse outcomes • Risk factors
• Patient related• Systems related
Lexico.com/en/definition/polypharmacy (from Oxford dictionary)Halli-Tierney A, et al. AAFP. 2019; 100(1):32-38.Masnoon N, et al. BMC Geriatrics (2017) 17:230
9
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Multimorbidity
• “The coexistence of multiple health conditions”• Often, two or more chronic conditions
• Associated with many challenges• Polypharmacy• Complex visits with multiple clinicians• Lack of clinical data/studies
Johnston MC, et al. EJPH. 2019; 29(1):182-9.
10
10/8/21
6
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Geriatric Syndromes
Adapted from: Inouye SK, et al. J Am Geriatric Society. 2007 May; 55(5): 780-791.
RISK
FA
CTO
RS GERIATRIC SYNDROMESPolypharmacyFallsIncontinencePressure UlcersDelirium
FRAI
LTY POOR
OUTCOMESDisabilityNursing HomeDeath
11
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Age Related Changes
• Physiologic changes • Pharmacokinetic changes
• Absorption• Distribution • Metabolism• Elimination
• Pharmacodynamic changes • Decreases in receptors
Change Result
A↓ Active transport↓ First pass Unpredictable bioavailability
D ↓ Total body water↑ Total body fat
↓ Vd for water soluble drugs↑ Vd for fat soluble drugs
M↓ Phase I metabolism↓ Hepatic blood flow ↓ Metabolism = ↑ t1/2
E ↓ Renal elimination ↑ t1/2
Hämmerlein A, et al. Clinical Pharmacokinetics. 1998; 35(1):49-64.
12
10/8/21
7
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Functional and Cognitive Limitations
• Functional changes• Hearing loss• Reduced physical activity• Decreased motor skills
• Cognitive changes• Increased processing time • Decreased attention • Decline in “new” learning abilities• Decline in executive cognitive
function
Limitation and changes can also be related to chronic disease and multimorbidity
13
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Limited Evidence
• Lack of guidelines • Particularly, to discontinue
medications• Exclusion of older adults with
multimorbidity
• Biases in literature • Recruitment bias • Misclassification bias
Image from: https://pharma.elsevier.com/pharmacovigilance/the-role-of-scientific-literature-in-pharmacovigilance/
14
10/8/21
8
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Self-Assessment Question #1
Which of the following contribute to the complexity of caring for geriatric patients?
A. Pharmacokinetic changes B. PolypharmacyC. Limited evidence D. All of the above
15
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Deprescribing
16
10/8/21
9
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Deprescribing
• “Deprescribing is the planned and supervised process of dose reduction or stopping of medication that might be causing harm, or no longer be of benefit.”• Deprescribing.org
• Systematic process to:• Identify medications that may cause harm • Discontinue those medications
• Patient-centered intervention
17
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Why deprescribe?
Reduce Polypharmacy
Improve Health Outcomes
Prevent Adverse Events
Improve Medication Adherence
Increase Patient Satisfaction
Reduce Healthcare Costs
18
10/8/21
10
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Polypharmacy + Geriatric SyndromesMedication Class Geriatric Syndrome
Anticholinergics OpioidsCalcium channel blockers Constipation
Anticholinergics CorticosteroidsBenzodiazepines H2-receptor antagonists Delirium
Anticholinergics SulfonylureasAntihypertensives Dizziness
AntihypertensivesCentrally acting medications Falls
Diuretics Sedative hypnoticsOpioids Urinary Incontinence
Adapted from: McGrath, et al. JFP 2017; 66(7).
19
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Can Deprescribing Prevent Geriatric Syndromes?
• If, treatment of geriatric syndrome consists of:• Identifying and treating related disease states • Risk assessment and reduction
• And, deprescribing identifies and removes medications that may cause harm • Then, deprescribing can prevent geriatric syndromes
Deprescribing is a Proactive Approach!
20
10/8/21
11
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Deprescribing ApproachIdentify
Prioritize
Discuss
Implement
Follow-up
Review
Deprescribing
21
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Assessing Medication Regimens: Patient Case
Mr. Taylor is a 74 year-old-male with a history of hypertension, hyperlipidemia, GERD, benign prostatic hyperplasia, osteoarthritis of the knee, and insomnia. He presents to the clinic today for a medication review.
Age: 74 yearsHeight: 70 inchesWeight: 182 lbs
Pertinent Labs
Na 140 mmol/L Hgb 14 g/dL
K 4.2 mmol/L Hct 42%
Cl 102 mmol/L WBC 5.2
CO2 20 mmol/L Plt 240
SCr 1.2 mg/dL HgbA1c 6.8%
BUN 12 mmol/L Glucose 138 mg/dL
Vital Signs
HR 66
BP 124/82
Temp 98.2
RR 18
22
10/8/21
12
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Patient Case: Mr. Taylor
Past Medical History:• Hypertension• Hyperlipidemia• GERD• BPH • Osteoarthritis• Insomnia
Home Medications:• Amlodipine 10mg PO daily • Lisinopril 20mg PO daily • Rosuvastatin 40mg PO daily • Pantoprazole 40mg PO daily• Tamsulosin 0.4mg PO daily • Oxycodone/Acetaminophen
5/325mg, 1 to 2 tabs PO q6h PRN pain• Amitriptyline 25mg PO HS • Zolpidem 10mg PO HS
23
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Assess the Medication Regimen
Indication
Duplication
Dosing
Interactions
Risk-Benefit
Patient Factors
24
10/8/21
13
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Tools to Evaluate the Medication Regimen
• Potentially inappropriate medications
Beers Criteria & STOPP
• Criteria to determine appropriateness
Medication Appropriateness Index
• Identify medications with a high anticholinergic burden
Anticholinergic Burden Calculator
• Tool to optimize drug therapy management
Fit FOr The Aged (FORTA)
25
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Tools to Evaluate the Medication Regimen
• Review all medications the patient has at home
Brown Bag Method
• Enter medication list for specific patient
MedStopper.com
• Medication fall risk score and evaluation tools
AHRQ 3I tool & CDC: STEADI tool
• Ten medications older adults should avoid or use with caution
Health in Aging
26
10/8/21
14
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Self-Assessment Question #2
After reviewing Mr. Taylor’s medication regimen, can you identify all ofthe medications that may put this patient at risk for developing a geriatric syndrome?
A. Lisinopril, Rosuvastatin, PantoprazoleB. Amlodipine, Lisinopril, Tamsulosin, Oxycodone/APAP, Amitriptyline,
ZolpidemC. Oxycodone/APAP, Zolpidem, AmitriptylineD. Amlodipine, Lisinopril, Rosuvastatin, Tamsulosin, Oxycodone/APAP,
Amitriptyline, Zolpidem
27
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Patient Case: Mr. TaylorMedication Geriatric Syndrome
Anticholinergics OpioidsCalcium channel blockers Constipation
Anticholinergics CorticosteroidsBenzodiazepines H2-receptor antagonists Delirium
Anticholinergics SulfonylureasAntihypertensives Dizziness
AntihypertensivesCentrally acting medications Falls
Diuretics Sedative hypnoticsOpioids Urinary Incontinence
28
10/8/21
15
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Prioritize Medications
1.Medications that have already caused an adverse event
2.Medications most likely to cause the greatest harm
3.One medication that can cause multiple geriatric syndromes
4.Medications with safer alternatives
5.
Unnecessary medicationsNo indication Duplication of therapy
29
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Self-Assessment Question #3
After identifying medications that can cause geriatric syndromes in Mr. Taylor’s medication regimen, how would you prioritize deprescribing?
A. Oxycodone/APAP, Zolpidem, AmitriptylineB. Amlodipine, Oxycodone/APAP, ZolpidemC. Lisinopril, Amlodipine, TamsulosinD. Oxycodone/APAP, Amlodipine, Tamsulosin
30
10/8/21
16
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Deprescribing Algorithms
• Deprescribing.org• Evidence based guidelines and
algorithms• Antihyperglycemics• Antipsychotics• Benzodiazepines• Cholinesterase Inhibitors and
Memantine • Proton Pump Inhibitors
• Educational tools for patients
Image from: Deprescribing.org
31
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Deprescribing Algorithms
• Primary Health Tasmania• Evidence based guides
• Consumer resources • https://www.primaryhealthtas.com.au/
resources/deprescribing-resources/
• Allopurinol • Cholinesterase Inhibitors• Antihyperglycemics • Glaucoma eye drops• Antihypertensives • NSAIDs• Antipsychotics • Opioids• Aspirin • Proton Pump Inhibitors• Benzodiazepines • Statins• Bisphosphonates • Vitamin D and Calcium
Image from: Primary Health Tasmania
32
10/8/21
17
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Avoiding Withdrawal Events
• Tapering algorithms • Use to avoid adverse drug
withdrawal events • Can stop many drugs without
withdrawal reactions
• If there is concern for adverse withdrawal events, and no guideline exists:• Taper slowly, over 4-6 weeks • Monitor patient closely
Medications That Can be Stopped without Tapering
ACE/ARB (for nephroprotection) 5-⍺ Reductase Inhibitors
Antibiotics (prophylaxis) Memantine
Antihyperglycemics (oral) Multivitamins
Anti-platelets NSAIDs
Bisphosphonates Nutritional Supplements
Calcium + Vitamin D Statins
Estrogen (for menopausal symptoms) Theophylline
Adapted from: Hanlon JT, Tjia J. Sr Care Pharm 2021; 36:136-41.
33
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Medications that Require TaperingMedication Class Withdrawal Reaction Tapering Duration
Anticholinergics Irritability, anxiety, insomnia 4 – 8 weeks
Antiepileptics Seizure recurrence 3 – 6 months
Antipsychotics Dyskinesias, overactivity 1st generation: 1 – 2 weeks2nd generation: 4 – 8 weeks
Beta Blockers Tachycardia, rebound HTN 3 – 4 months
Benzodiazepines Anxiety, insomnia, tremor 1 – 2 months
Central ⍺-blockers Rebound hypertension 3 – 6 weeks
CorticosteroidsAnorexia, lethargy, arthralgia, postural hypotension Several months
H-2 receptor antagonists (H2RA) Proton Pump Inhibitors (PPI) Rebound gastric hypersecretion 4 weeks
Adapted from: Hanlon JT, Tjia J. Sr Care Pharm 2021; 36:136-41.
34
10/8/21
18
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Perspectives
35
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Pharmacist Perspective
• Understand importance of deprescribing • Interpret data • Communicate across healthcare team
• Medication review and recommendations • Utilize literature• Apply evidence based algorithms • Discuss with physician• Counsel patient
• Goal to collaborate with physician
36
10/8/21
19
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Pharmacy Technician Perspective
• Perform medication reconciliation in the inpatient setting• Obtain preadmission medication list • Contact outpatient pharmacies and physician offices • Document complete medication list
• Upon discharge, list sent to:• Primary care physician
• Accurate medication list is key to deprescribing efforts
• Home with patient
• Collaborate with pharmacist when polypharmacy is identified
37
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Physician Perspective
• View deprescribing as a therapeutic intervention • Practice prudent prescribing• Patients are more likely to consider deprescribing if recommended by a
trusted physician • Importance of a streamlined medication reconciliation process• Challenges
• Time constraints • Multiple prescribers• Multiple pharmacies • Prescribing cascade
• Goal to collaborate with pharmacist
38
10/8/21
20
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Pharmacy + Physician Team
• Key role in managing polypharmacy• Areas for collaboration
• Recommendations regarding drug therapy• Over the counter medication selection • Patient counseling • Identification of medication side effects • Improving medication adherence • Advise regarding drug interactions
• Challenges• Community setting• Reimbursement • Experience• Time
39
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Patient Perspective
• Willingness to deprescribe influenced by:• Perception of medication appropriateness • Fear of adverse outcomes • Involvement of regular primary care physician• Understanding of why deprescribing is important• Previous experiences
• Caregiver perspective• Influenced by complexity
40
10/8/21
21
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Communicating with Patients
• Consider goals • Ask the right questions!• Discuss options, introduce choice, make decisions:
• Several medications you are taking have side effects that may be contributing to your dizziness
• If you are open to it, we can reduce the dose or stop one of these medications to see if your dizziness improves
• How do you feel about this? • What questions do you have for me?
Adapted from: Farrell B, Mangin D. AAFP, 2019; 99(1): 7-9
41
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Patient Case
42
10/8/21
22
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Mrs. Brown
Mrs. Brown is a 78-year-old female with a recent fall at home. The fall occurred at night when she was getting up to use the bathroom. This is the first fall she has had. She lives at home with her husband. She presents to the clinic today for a follow up appointment.
Age: 78 yearsHeight: 64 inchesWeight: 144 lbsImaging: normalMicro: UA no growth
Pertinent Labs
Na 138 mmol/L Hgb 12 g/dL
K 4.0 mmol/L Hct 36%
Cl 104 mmol/L WBC 4.6
CO2 22 mmol/L Plt 200
SCr 1.0 mg/dL HgbA1c 7.2%
BUN 10 mmol/L Glucose 144 mg/dL
Vital Signs
HR 58
BP 110/72
Temp 98.4
RR 16
43
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Mrs. Brown
Past Medical History:• Hypertension • Hyperlipidemia • Depression• Anxiety • Incontinence• Osteoporosis• Recent Fall
Home Medications:• Lisinopril 10mg PO daily• Hydrochlorothiazide 12.5mg PO daily• Atorvastatin 80mg PO daily• Escitalopram 10mg PO daily• Lorazepam 0.5mg PO TID PRN • Oxybutynin ER 10mg PO daily• Calcium/Vitamin D 600mg/400 IU PO
daily
44
10/8/21
23
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Self-Assessment Question #4
Which diagnoses does Mrs. Brown have that would be considered geriatric syndromes?
A. HypertensionB. IncontinenceC. FallsD. B and C
45
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Self-Assessment Question #5
Could any of the medications Mrs. Brown is taking contribute to geriatric syndromes?
A. Hydrochlorothiazide B. OxybutyninC. LorazepamD. All of the above
46
10/8/21
24
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Mrs. Brown: Collaboration
• Prior to seeing Mrs. Brown in the office, the physician and pharmacist meet to discuss a plan • Would like to deprescribe one or more medications• Determine that more information is needed to develop a plan
• Key discussion points with Mrs. Brown: • Timing of lorazepam before the fall • Frequency of lorazepam usage• Urinary incontinence history • Symptoms prior to fall
47
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Mrs. Brown: Additional Information
• How often do you take your lorazepam?• “I only take it when I can’t sleep. On average, I take it two times a month.”
• How long have you been taking lorazepam? • “I first got the prescription 10 or 15 years ago after my neighbor passed away. We were close
friends, and I was was very worried about how I would get on without her. I took the medicine a lot more back then. Now, I just keep it around because I find it useful to help me sleep.”
• What time did you last take your lorazepam before your fall? • “I took it at 8 or 8:30pm.”
• Did you take your lorazepam that evening to help with sleep? • “Yes. Our 14-year-old cat has been sick lately. We had an appointment to take her to the
veterinarian the next morning, and I was worried about the diagnosis. I was thinking too much about it, and couldn’t fall asleep.”
• Did you try anything else to help with your symptoms that night?• “No, I didn’t. Sometimes I take a melatonin pill before I take the lorazepam, but I was out of
them.”
48
10/8/21
25
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Mrs. Brown: Additional Information
• How long have you been suffering from urinary incontinence? • “Probably 5 years. When I have to go, I have to go! I figured it’s just part of getting old.”
• Was it before or after you started taking hydrochlorothiazide? • “Well, I started taking it about 7 or 8 years ago. So I think my bladder issues came after I
started the water pill.”
• How often do you get up during the night to use the bathroom? • “At least once every night. Sometimes twice. Usually I am very thirsty, so I have a glass of
water when I get up too. Come to think of it, that probably makes my bladder issues worse.”• Did you feel any different than normal before you fell?
• “Well, I got up to go to the bathroom. I was in the hallway, and I started to feel dizzy. There wasn’t anything to hold on to, so I fell to the floor. I wouldn’t say that it was very different though. I have had quite a few dizzy spells lately. It was something I wanted to talk to you about today.”
• How often do you experience dizziness?• “Oh, I feel dizzy for a minute or two almost every day now. It started about two months ago.”
49
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Mrs. Brown: Polypharmacy + Geriatric Syndromes
• Taking greater than 5 medications• Evaluate all medications
associated with geriatric syndromes for deprescribing
• By deprescribing now, we can:• Prevent future medication related
adverse events • Increase quality of life
Geriatric Syndrome Associated Medications
Falls/Dizziness
HydrochlorothiazideLisinoprilLorazepamOxybutynin
Urinary Incontinence HydrochlorothiazideOxybutynin
Polypharmacy all
50
10/8/21
26
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Self-Assessment Question #6
We have identified that we should consider deprescribing Mrs. Brown’s hydrochlorothiazide, lisinopril, lorazepam and oxybutynin. Based on the information gathered during your discussion with Mrs. Brown, which medication would you prioritize to deprescribe first?
A. Hydrochlorothiazide B. LisinoprilC. LorazepamD. Oxybutynin
51
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Mrs. Brown: Deprescribing Benzodiazepines
• Mrs. Brown no longer has an appropriate indication for lorazepam• Discussion with Mrs. Brown about
risks and benefits of tapering• She is in agreement
• Implement tapering plan• Dose reduction to 0.25mg• Frequency reduction to HS PRN
• Follow-up phone call in 2 weeks, Follow-up visit in 4 weeks
52
10/8/21
27
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Mrs. Brown: 8 Week Follow-up
Identify
Prioritize
Discuss
Implement
Follow-up
Review
• Mrs. Brown is completely tapered off lorazepam• She has not had any falls!
• She is still struggling with urge incontinence• Discuss deprescribing
hydrochlorothiazide • She is in agreement • Follow-up on BP and frequency of
urge incontinence in 4 weeks• If improved, can taper off
oxybutynin
Deprescribing
53
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Mrs. Brown: Discussion
• Other ideas on how to approach this patient?• Have you used any of these deprescribing techniques in practice? • Thoughts on pharmacist – physician collaboration?
54
10/8/21
28
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
Summary
• Deprescribing is a proactive approach to prevent geriatric syndromes • Identify• Prioritize• Discuss • Implement• Follow-up• Review
• Collaboration between physician, pharmacy team, and patient are key to successful deprescribing • Key resources:
• Beer’s Criteria, STOPP, Medication Appropriateness Index, FORTA• Deprescribing.org and Primary Health Tasmania
55
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
References • American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older
Adults. J Am Geriatr Soc. January 2019.
• American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Patient-centered care for older adults with multiple chronic conditions: a stepwise approach from the American Geriatrics Society: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012;60(10):1957-1968.
• Deprescribing.org. What is deprescribing? https://deprescribing.org/what-is-deprescribing/
• Endsley, S. Deprescribing unnecessary medications: a four part process. American Academy of Family Physicians. 2018; 25(3):28-32.
• Fabiili NA, Powers MF. Roles for pharmacy technicians in medication reconciliation during transitions of care. Journal of Pharmacy Technology. 2017 Feb; 33(1): 3–7.
• Farrell B, Mangin D. Deprescribing is an essential part of good prescribing. American Academy of Family Physicians. 2019; 99(1):7-9.
• Farrell B, Pottie K, Thompson W et al. Deprescribing proton pump inhibitors. Canadian Family Physician. 2017; 63:354-64.
• Halli-Tierney A, Scarbrough C, Carroll D. Polypharmacy: evaluating risks and deprescribing. American Family Physician. 2019; 100(1):32-38.
• Hämmerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clinical Pharmacokinetics. 1998; 35(1):49-64.
• Hanlon JT, Tjia J. Avoiding adverse drug events when stopping unnecessary medications according to the STOPPFrail criteria. Senior Care Pharmacist. 2021; 36:136-41.
• Inouye SK, et al. Geriatric syndromes: Clinical research and policy implications of a core geriatric concept. J Am Geriatric Society. 2007 May; 55(5): 780-791.
• Johnston MC, Crilly M, Black C, et al. Defining and measuring multimorbidity: a systematic review of systematic reviews. Eur J Public Health. 2019; 29(1):182-9.
• Kelly DV, Bishop L, Young S, et al. Pharmacist and physician views on collaborative practice: findings from the community pharmaceutical care project. Canadian Pharmacists Journal. 2013; 146(4):218-26.
• Krishnaswami A, Steinman MA, Goyal P, et al. Deprescribing in older adults with cardiovascular disease. Journal of the American College of Cardiology. 2019; 73(20):2584-95.
• Kuhn-Thiel AM, Weiß C, Wehling M; FORTA authors/expert panel members. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014 Feb;31(2):131-40.
• Lexico.com/en/definition/polypharmacy (from Oxford dictionary)
• Magnuson A, Sattar S, Nightingale G, et al. A practical guide to geriatric syndromes in older adults with cancer: A focus on falls, cognition, polypharmacy and depression. American Society of Clinical Oncology. 2019; e96-109.
56
10/8/21
29
2021 Annual Meeting & ExhibitionNovember 4-7, 2021 | San Diego, California
References• Markota M, Rummans TA, Bostwick JM et al. Benzodiazepine use in older adults: Dangers, management, and alternative therapies. Mayo Clinic Proceedings. 2016; 1632-9.
• Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics (2017) 17:230
• Maust DT, Lin LA, Goldstick JE et al. Association of Medicare part D benzodiazepine coverage expansion in fall-related injuries and overdoses among Medicare Advantage beneficiaries. JAMA Network Open. 2020; 3(4): e202051.
• McGrath K, Hajjar ER, Kumar C, et al. Deprescribing: a simple method for reducing polypharmacy. Journal of Family Practice. 2017; 66(7):436-45.
• Murman DL. The impact of age on cognition. Semin. Hear. 2015;36:111–121.
• National Council on Aging. Falls Prevention. https://www.ncoa.org/healthy-aging/falls-prevention/
• O'Mahony, O'Sullivan, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 Age Ageing (2015) 44 (2): 213-218 doi:10.1093/ageing/afu145
• Olde Rikkert MGM, Rigaud AS, van Hoeyweghen RJ, de Graaf J. Geriatric syndromes: medical misnomer or progress in geriatrics? Netherlands Journal of Medicine. 2003; 61(3):83-7.
• Page AT, Clifford RM, Potter K, et al. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. British Journal of Clinical Pharmacology. 2016; 82:583-623.
• Pottie K, Thompson W, Davies S et al. Deprescribing benzodiazepine receptor agonists. Canadian Family Physician. 2018; 64:339-51.
• Primary Health Tasmania. Deprescribing Resources. https://www.primaryhealthtas.com.au/resources/deprescribing-resources/
• Reeve E, Farrell B, Thompson W et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Medical Journal of Australia. 2019; 210(4):174-9.
• Reeve E, Low L, Hilmer S. Beliefs and attitudes of older adults and carers about deprescribing of medications: a qualitative focus group study. British Journal of General Practice. 2016; 66(649): e552-60.
• Stevens JA. The STEADI Tool Kit: A fall prevention resource for health care providers. IHS Prim Care Provid. 2013 Sep: 39(9); 162-166.
• Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Canadian Journal of Hospital Pharmacy. 2013; 66(3):201-2.
• Tool 3I: Medication Fall Risk Score and Evaluation Tools. Content last reviewed January 2013. Agency for Healthcare Research and Quality, Rockville, MD. https://www.ahrq.gov/professionals/systems/hospital/fallpxtoolkit/fallpxtk-tool3i.htm
• Turnheim K. When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly. Experimental Gerontology. 2003; 38:843-53.
57
Recommended